LOGIN
Fondaparinux Sodium Vs Low-Molecular-Weight Heparin For Deep Vein Thrombosis During THA
August 2024
Fondaparinux Sodium Vs Low-Molecular-Weight Heparin For Deep Vein Thrombosis During THA
Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:1
A Comparison Between Fondaparinux Sodium and Low-Molecular-Weight Heparin in Preventing Patients Undergoing Hip Replacement from Deep Vein Thrombosis.
J Musculoskelet Neuronal Interact . 2024 Jun 1;24(2):185-191.Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
Sixty patients undergoing total hip arthroplasty were randomized to receive either fondaparinux sodium (n=30) or low-molecular-weight heparin (n=30). Outcomes of interest included the incidence of deep vein thrombosis (DVT) after surgery, Wells scores, subcutaneous ecchymosis, swelling circumference, and Visual Analogue Scale (VAS) pain scores. Outcomes were assessed at 3, 5, and 7 days postoperat...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.